Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Slides:

Advertisements

Similar presentations

Use of the diagonal mattress suture to prevent dog-ear formation

Advertisements

Yin-Shuo Chang, MD, Yu-Chen Huang, MD

Clavi syphilitici–an unusual presentation of syphilis

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Alexander Egeberg, MD, PhD, Lone Skov, MD, PhD, DMSc, Aditya A

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

A girl with a solitary red bulla

Facial adenocarcinoma treated with intra-arterial chemotherapy

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis is associated with lipid abnormalities at the onset of skin disease Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: Report of three cases Xiaoqing.

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce Strober, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Treatment of toxic epidermal necrolysis in North America

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Reply to: “Comment on ‘Activation of melanocytes in idiopathic guttate hypomelanosis after 5-fluorouracil infusion using a tattoo machine: Preliminary.

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Reply to: “A note on normality”

Alopecia areata Journal of the American Academy of Dermatology

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Mark D. Heibel, MD, Haley D. Heibel, MS JAAD Case Reports

Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis Amalie.

Solomon Shockman, MD, Lauren Krug, MD, Nektarios Lountzis, MD

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Hugh Gloster, MD, Chesahna Kindred, MBA

Appearance of lentigines in psoriasis patients treated with apremilast

Medicaid acceptance among pediatric dermatologists

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

Descriptive survival study of nail melanoma patients treated with functional surgery versus distal amputation Suelen Montagner, MD, Francisco Aparecido.

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3 Alexander Egeberg, MD, PhD, Jashin J. Wu, MD, Neil Korman, MD, PhD, James A. Solomon, MD, PhD, Orin Goldblum, MD, Fangyi Zhao, PhD, Lotus Mallbris, MD, PhD Journal of the American Academy of Dermatology Volume 79, Issue 1, Pages 104-109.e8 (July 2018) DOI: 10.1016/j.jaad.2018.02.074 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Low-density lipoprotein (LDL)-to–high-density lipoprotein (HDL) ratio in the induction period (UNCOVER-1, UNCOVER-2, and UNCOVER-3; weeks 0-12) and maintenance period (UNCOVER-1 and UNCOVER-2; weeks 12-60; only placebo [PBO] and ixekizumab every 4 weeks [IXEQ4W]) when patients were treated with PBO, IXEQ4W, or ixekizumab every 2 weeks (IXEQ2W). Induction period results derived from the primary psoriasis placebo-controlled integrated analysis set, and maintenance period results derived from the psoriasis maintenance integrated analysis set. Journal of the American Academy of Dermatology 2018 79, 104-109.e8DOI: (10.1016/j.jaad.2018.02.074) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1 Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3 were integrated into the primary psoriasis placebo-controlled integrated analysis set (weeks 0-12; UNCOVER-1, UNCOVER-2, and UNCOVER-3) (A), the primary psoriasis placebo- and active-controlled integrated analysis set (weeks 0-12; UNCOVER-2 and UNCOVER-3) (B), and the psoriasis maintenance integrated analysis set (weeks 12-60; UNCOVER-1 and UNCOVER-2) (C). ETN, Etanercept; IXEQ2W, ixekizumab every 2 weeks; IXEQ4W, ixekizumab every 4 weeks; PBO, placebo. Journal of the American Academy of Dermatology 2018 79, 104-109.e8DOI: (10.1016/j.jaad.2018.02.074) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 2 Low-density lipoprotein (LDL)-to–high-density lipoprotein (HDL) ratio in the ixekizumab integrated induction period for UNCOVER-2 and UNCOVER-3 (psoriasis placebo- and active-controlled integrated analysis set) when patients were treated with placebo (PBO), ixekizumab every 4 weeks (IXEQ4W), ixekizumab every 2 weeks (IXEQ2W), or etanercept (ETN) biweekly. Journal of the American Academy of Dermatology 2018 79, 104-109.e8DOI: (10.1016/j.jaad.2018.02.074) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions